vs
Ultragenyx Pharmaceutical Inc.（RARE）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.0倍（$217.4M vs $207.3M），Rapid7, Inc.净利率更高（1.4% vs -62.0%，领先63.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.0%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
RARE vs RPD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $217.4M |
| 净利润 | $-128.6M | $3.1M |
| 毛利率 | — | 68.9% |
| 营业利润率 | -54.7% | 1.0% |
| 净利率 | -62.0% | 1.4% |
| 营收同比 | 25.9% | 0.5% |
| 净利润同比 | 3.5% | 44.1% |
| 每股收益（稀释后） | $-1.28 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $207.3M | $217.4M | ||
| Q3 25 | $159.9M | $218.0M | ||
| Q2 25 | $166.5M | $214.2M | ||
| Q1 25 | $139.3M | $210.3M | ||
| Q4 24 | $164.6M | $216.3M | ||
| Q3 24 | $139.5M | $214.7M | ||
| Q2 24 | $147.0M | $208.0M | ||
| Q1 24 | $108.8M | $205.1M |
| Q4 25 | $-128.6M | $3.1M | ||
| Q3 25 | $-180.4M | $9.8M | ||
| Q2 25 | $-115.0M | $8.3M | ||
| Q1 25 | $-151.1M | $2.1M | ||
| Q4 24 | $-133.2M | $2.2M | ||
| Q3 24 | $-133.5M | $15.4M | ||
| Q2 24 | $-131.6M | $6.5M | ||
| Q1 24 | $-170.7M | $1.4M |
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% | ||
| Q1 24 | — | 70.3% |
| Q4 25 | -54.7% | 1.0% | ||
| Q3 25 | -106.9% | 2.7% | ||
| Q2 25 | -64.8% | 1.6% | ||
| Q1 25 | -102.6% | -0.0% | ||
| Q4 24 | -74.3% | 3.4% | ||
| Q3 24 | -94.6% | 6.0% | ||
| Q2 24 | -79.1% | 2.5% | ||
| Q1 24 | -151.9% | 4.7% |
| Q4 25 | -62.0% | 1.4% | ||
| Q3 25 | -112.8% | 4.5% | ||
| Q2 25 | -69.0% | 3.9% | ||
| Q1 25 | -108.5% | 1.0% | ||
| Q4 24 | -80.9% | 1.0% | ||
| Q3 24 | -95.7% | 7.2% | ||
| Q2 24 | -89.5% | 3.1% | ||
| Q1 24 | -156.8% | 0.7% |
| Q4 25 | $-1.28 | $0.05 | ||
| Q3 25 | $-1.81 | $0.15 | ||
| Q2 25 | $-1.17 | $0.13 | ||
| Q1 25 | $-1.57 | $0.03 | ||
| Q4 24 | $-1.34 | $0.08 | ||
| Q3 24 | $-1.40 | $0.21 | ||
| Q2 24 | $-1.52 | $0.09 | ||
| Q1 24 | $-2.03 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-80.0M | $154.7M |
| 总资产 | $1.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $474.7M | ||
| Q3 25 | $202.5M | $407.1M | ||
| Q2 25 | $176.3M | $511.7M | ||
| Q1 25 | $127.1M | $493.5M | ||
| Q4 24 | $174.0M | $521.7M | ||
| Q3 24 | $150.6M | $443.7M | ||
| Q2 24 | $480.7M | $442.6M | ||
| Q1 24 | $112.3M | $411.7M |
| Q4 25 | $-80.0M | $154.7M | ||
| Q3 25 | $9.2M | $127.2M | ||
| Q2 25 | $151.3M | $90.4M | ||
| Q1 25 | $144.2M | $52.7M | ||
| Q4 24 | $255.0M | $17.7M | ||
| Q3 24 | $346.8M | $-5.1M | ||
| Q2 24 | $432.4M | $-52.6M | ||
| Q1 24 | $140.3M | $-86.4M |
| Q4 25 | $1.5B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.3B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | $36.4M |
| 自由现金流率自由现金流/营收 | -48.6% | 16.8% |
| 资本支出强度资本支出/营收 | 0.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $-472.0M | $146.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-99.8M | $37.6M | ||
| Q3 25 | $-91.4M | $39.0M | ||
| Q2 25 | $-108.3M | $47.5M | ||
| Q1 25 | $-166.5M | $29.8M | ||
| Q4 24 | $-79.3M | $63.8M | ||
| Q3 24 | $-67.0M | $44.0M | ||
| Q2 24 | $-77.0M | $32.9M | ||
| Q1 24 | $-190.7M | $31.1M |
| Q4 25 | $-100.8M | $36.4M | ||
| Q3 25 | $-92.7M | $34.8M | ||
| Q2 25 | $-110.7M | $46.6M | ||
| Q1 25 | $-167.8M | $28.4M | ||
| Q4 24 | $-79.5M | $62.6M | ||
| Q3 24 | $-68.6M | $42.6M | ||
| Q2 24 | $-79.0M | $32.6M | ||
| Q1 24 | $-193.9M | $30.4M |
| Q4 25 | -48.6% | 16.8% | ||
| Q3 25 | -58.0% | 16.0% | ||
| Q2 25 | -66.5% | 21.8% | ||
| Q1 25 | -120.5% | 13.5% | ||
| Q4 24 | -48.3% | 28.9% | ||
| Q3 24 | -49.2% | 19.9% | ||
| Q2 24 | -53.7% | 15.7% | ||
| Q1 24 | -178.2% | 14.8% |
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 0.8% | 1.9% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 1.0% | 0.6% | ||
| Q4 24 | 0.1% | 0.5% | ||
| Q3 24 | 1.2% | 0.6% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 3.0% | 0.3% |
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
